New heart pump to begin US trials:
This article was originally published in Clinica
Cardiac Assist Technologies has begun an FDA-approved clinical trial of its heart pump in the US. The five-patient feasibility trial under an Investigational Device Exemption, will be carried out to evaluate the safety of the AB-180 CSS ventricular assist device and to fine-tune the clinical protocol in preparation for multi-centre clinical trials of the device. The Pittsburgh-based company has also begun clinical studies of the device in the UK, Switzerland and South Africa.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.